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ABSTRACT 
Purpose: A number of independent gene expression profiling studies have identified 
transcriptional subtypes in colorectal cancer (CRC) with potential diagnostic utility, 
culminating in publication of a CRC Consensus Molecular Subtype classification. 
The worst prognostic subtype has been defined by genes associated with stem-like 
biology. Recently, it has been shown that the majority of genes associated with this 
poor prognostic group are stromal-derived. We investigated the potential for tumor 
misclassification into multiple diagnostic subgroups based on tumoral region 
sampled. 
Experimental design: We performed multi-region tissue RNA 
extraction/transcriptomic analysis using Colorectal Specific Arrays on invasive front, 
central tumor and lymph node regions selected from tissue samples from 25 CRC 
patients. 
Results: We identified a consensus 30 gene list which represents the intratumoral 
heterogeneity within a cohort of primary CRC tumors. Using a series of online 
datasets, we showed that this gene list displays prognostic potential (HR=2.914 (CI 
0.9286-9.162) in stage II/III CRC patients, but in addition we demonstrated that these 
genes are stromal derived, challenging the assumption that poor prognosis tumors 
with stem-like biology have undergone a widespread Epithelial Mesenchymal 
Transition (EMT). Most importantly, we showed that patients can be simultaneously 
classified into multiple diagnostically relevant subgroups based purely on the tumoral 
region analysed. 
Conclusion: Gene expression profiles derived from the non-malignant stromal 
region can influence assignment of CRC transcriptional subtypes, questioning the 
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current molecular classification dogma and highlighting the need to consider 
pathology sampling region and degree of stromal infiltration when employing 
transcription-based classifiers to underpin clinical decision-making in CRC.  
 
Translational relevance: Recent molecular profiling studies in CRC have identified 
distinct subgroups with significant prognostic value. These studies have proposed 
the use of transcriptional-based companion diagnostic tests, based on these 
prognostic subgroups. In stage II/III CRC, such diagnostic tests are urgently needed 
to inform clinical decision-making in regard to administration of adjuvant therapy 
following surgery. The identification of a poor prognostic group has been associated 
with EMT- and Stem-like traits, although detailed analysis of these tumors has 
revealed that the stromal-rich architecture of the tumor microenvironment informs 
their biology. In this study, we highlight the contrasting gene expression at multiple 
regions of CRC primary tumors due to intratumoral heterogeneity. This differential 
biology itself displays prognostic value and overlaps with the proposed diagnostic 
classifier signatures in CRC. Further to this, we highlight the potential for individual 
patient misclassification due to this regional heterogeneity using the recently 
proposed molecular classifiers. 
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INTRODUCTION 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the 
Western world. To date, the most powerful prognostic classification tool in CRC still 
relies on the Tumor Node Metastasis (TNM) staging system. While histopathology is 
able to identify a number of factors which provide additional prognostic value and 
capture biological aspects of important disease processes, (such as tumor 
morphology, grade and stage, lymphovascular invasion and peritumoral 
inflammation), it gives no insight into the distinct biology that underpins CRC and 
determines disease outcome.  
 
We and others have employed transcriptional profiling of clinically-annotated tumor 
samples to gain molecular insights into CRC biology and thereby develop new 
patient stratification tools and identify novel therapeutic approaches (1-6). Using 
unsupervised classification of transcription data, independent groups have reported 
3-6 molecular subgroups within CRC (2, 4, 7). Recent subtype concordance analysis 
by the CRC Subtyping Consortium (CRCSC) has yielded a consensus of 4 
transcriptionally-driven CRC molecular subgroups (Consensus Molecular Subtype 
(CMS 1-4)) with the following distinguishing features: CMS1: Microsatellite 
instable(MI)/immune (frequency(f) =14%); CMS2: Canonical  (f=37%); CMS3: 
Metabolic (f=13%) and CMS4: Mesenchymal (f=23%)  (8, 9). Of these subgroups, 
the mesenchymal subtype (CMS4) has been found to be significantly associated with 
the worst prognosis in all studies. Additionally, this gene signature has also been 
detected in serrated precursor lesions, suggesting that aggressive tumor traits may 
be “imprinted” in dysplastic tissue at the very earliest stage.  
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Many of the studies highlighted above (2, 4, 7) suggested that the identification of 
the CMS4 subtype was evidence of epithelial tumor cells undergoing changes 
associated with an extensive epithelial-mesenchymal transition (EMT), resulting in 
increased invasion and the acquisition of stem cell properties that are necessary for 
the establishment of metastases (10). Although the findings of these studies were 
independently validated, the cells-of-origin of individual transcriptional subtypes were 
not defined. More recently, two studies have indicated that mesenchymal tumors 
have an enriched stromal component, suggesting that the origin of the CMS4 
signature may be dependent on the transcriptional profile originating from the 
stromal rather than the tumor compartment (11, 12). In this paper, we build on these 
recent studies and provide important insights into the role of the colorectal tumor 
stroma, which may have significant implications for transcription-based classifiers as 
precision medicine tools for patient stratification. 
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Materials and Methods 
 
Tissue samples 
Upon receipt in the histopathology laboratory, fresh colon resection specimens 
(resected for tumor) were examined by a pathologist.  Regions of interest (deep and 
superficial tumor) were identified using standard approaches and described for 
subsequent sampling.  Specimens were then fixed in 10% neutral buffered formalin, 
sampled and processed as per routine histology.  Subsequent examination of 3 µm 
H&E stained sections confirmed the presence of the identified regions of interest and 
examination of further material from the same resection identified lymph nodes 
positive for tumor metastasis.  The areas to be sampled were marked on the slides 
by a pathologist and these were then used as a guiding template for macro-
dissection of 10 µm unstained tissue sections cut from the same block.  Tissue of 
interest was scraped off the slide using a scalpel and a small amount of ethanol and 
placed in a labelled micro-centrifuge tube. 
 
Sample analysis 
We selected samples from 25 patients (for clinical details see Supplemental Table 1)  
where we had sufficient high quality material to extract RNA from regions of interest. 
This resulted in 75 transcription profiles, 25 patients’ samples at 3 regions per 
sample. These 75 samples were analyzed on the CRC disease specific array (DSA) 
platform (Almac). Initial QC analysis of the microarray data found that 2 samples 
were outliers and were subsequently removed from further downstream analyses, 
resulting in 73 transcriptional profiles; 24 invasive front, 24 central and 25 lymph 
node deposits. 
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Data analysis and classifier generation 
DSA arrays were read into the R statistical environment (version 3.1), background 
corrected and normalized using the justRMA function in the affy package. We initially 
assessed the profiles for dissimilarities by bootstrap hierarchical clustering to assess 
confidence in the groups and their distances by pvclust, allowing also for various 
non-specific gene filtering levels by the package genefilter. From here, the limma 
package was used to assess MDS plots as well as to perform differential expression 
analysis between contrasts and generation of the overlap by Venn diagram. In order 
to create a succinct list of genes that could best classify the central region against 
the invasive front, we adopted a machine learning method, pamr. Groups were 
stratified randomly into a three quarter training set and one quarter test set. We used 
genefilter’s ‘varFilter’ method to reduce the complexity of the features, which we also 
repeated for the pamr process at increasing stringencies to increase confidence in 
the list generated. We performed pamr analysis using a ten-fold cross-validation and 
chose our threshold to select the lowest misclassification rate (t= 2.0, 
misclassification = 5/36 and an overall error rate = 0.138). Using our initial 
classification run, pamr proffered a list of 58 features equating to 30 annotated 
genes. This annotated gene list formed the benchmark for dataset stratification in 
other independent datasets for the rest of this study. Hierarchical clustering 
performed in R was done using heatmap.plus using the Ward clustering method with 
Euclidean distance and with ordination of the data performed using correspondence 
analysis with the package made4 and visualized using the plotarrays parameter with 
differing graph arguments. 
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Independent datasets 
Affymetrix gene expression profiles from independent CRC datasets were 
downloaded from NCBI Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE14333, 
GSE35602, GSE33113, GSE39396 and GSE39582. In addition, the independent 
mouse dataset was accessed under GSE6383. Partek Genomics Suite was used on 
these series matrix files for independent dataset analysis. For the purpose of 
clustering, the data matrices were standardized to the median value of probe sets 
expression. Standardization of the data allows for the comparison of expression 
levels for different probe sets’, which may not necessarily be on the same scale or at 
the same intensity levels. Following standardization, 2-dimensional hierarchical 
clustering was performed using the Ward clustering method with Euclidean distance. 
 
Statistics 
Positive prediction value was calculated as PPV = number of true positives / number 
of positive calls. Negative prediction value was calculated as NPV = number of true 
negatives / number of negative calls. Sensitivity = number of true positives / number 
of true positives + number of false negatives. Specificity = number of true negatives / 
number of true negatives + number of false positives. 
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RESULTS 
Identification of region-specific transcriptomic profiles: 
In order to assess tumor heterogeneity at the level of transcription, we performed 
gene expression profiling on a cohort of patients (n=25, Supplementary Table 1) 
using tumor samples taken from multiple regions of the primary tumor, in addition to 
tumor tissue which had metastasized to regional lymph nodes (Supplementary 
Figure 1). The resulting transcriptomic data were analyzed using limma to identify 
differentially expressed genes. A supervised learning approach, pamr, was 
employed to extract a succinct list of genes that could highlight the contrasts 
between samples from different regions, which could then be visualized using a 
combination of a heatmap and hierarchical clustering.  
 
Determination of the number of genes which were differentially expressed (DE) 
between each region indicated that the transcriptome of the central tumor (CT) was 
more closely related to that of the invasive front (IF) than to that of the lymph node 
(LN) tumor tissue (Figure 1A and Supplementary Tables 2-4). However, both limma 
and pamr analyses revealed distinct differences between gene expression in the CT 
and IF, with a consistent upregulation of known drivers of disease progression, such 
as IGF1 (2.3–5-fold) and SFRP2 (2.6–4-fold) at the IF region, while upregulation of 
CXCL5 (3.3–8-fold), IL8 (3.6–4.4-fold) and MMP1 (2.6-7.9-fold) were consistently 
found in the CT region (Figure 1B, Supplementary Table 2).  
 
Using pamr classification, we extracted a concise gene list, comprising 30 annotated 
genes, that could identify and characterize the transcriptome associated with a 
minimum overall error (error rate = 0.138, Table 1). As expected, this gene list 
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contained a number of genes already reported to be involved in cancer progression, 
many of which were also represented in the DE gene list (Supplementary Table 2), 
such as IGF1, TGFB3, IL8, IL1B and WNT5A. We validated the gene list by applying 
it to the full cohort of IF and CT samples (Figure 1C) using hierarchical clustering to 
visualize ranges of expression. The region-of-origin was correctly identified in 44 out 
of 48 samples, giving this classifier a positive prediction value (PPV) for membership 
of IF equal to 91.7% and a corresponding negative prediction value (NPV) for 
membership of CT equal to 91.7%. 
 
Specific gene signatures identify tissue regions of origin 
To test the ability of stromal gene expression to classify tumor samples, we utilized a 
list of 213 genes, which are specifically expressed in cancer-associated fibroblasts 
(CAFs) (n=131), leukocytes (n=47) or endothelial cells (n=35) (11). Using this gene 
list, the samples from LN, CT and IF could be separated into 3 biological groups 
corresponding to their site of origin, using correspondence analysis of the top 
quartile most variant probes (Figure 2). Whereas Isella et al. (11) and Calon et al. 
(12) have shown that these 213 non-epithelial genes can be used to identify poor 
prognostic patients, we now demonstrate that the same genes can be used to 
identify the site of the tumor from which the sample has been taken. Moreover, the 
30 gene list (which we now define as a stromal classifier) was also able to correctly 
distinguish between tumor and stroma tissues in a cohort of 13 CRC tumor samples 
(GSE35620), each of which was micro-dissected into these two components, with no 
misclassification (Figure 3A, 3B). As a further validation, we used a tissue-specific 
dataset (GSE6383), which identified genes expressed in the mesenchymal and 
epithelial compartments of the perinatal mouse intestine (13). This analysis revealed 
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that the genes which we found to be overexpressed in IF compared to CT are highly 
expressed in the stromal mesenchyme fraction of the developing mouse intestine 
compared to the epithelium, and can stratify samples into regions of origin with no 
misclassification (Figure 3C). Collectively, these findings indicate that our 30 gene 
stromal classifier is an accurate identifier of tissue origin. 
 
To further delineate the source of the identified transcriptional signals to a precise 
cell-of-origin, we utilized microarray profiles derived from primary CRC tumors which 
have undergone disassociation and sorting in order to isolate cells into epithelial, 
endothelial, fibroblast and leukocytes compartments (GSE39396). Hierarchical 
clustering of our classifier using these cell sorted profiles indicated the upregulation 
of each transcript signal specifically in the fibroblast component, compared to the 
remaining tumor cell types (Figure 4A). Following median normalization for each 
individual gene across all four cell types, we again confirmed that the upregulation of 
the transcription levels for our classifier occurs specifically within the fibroblasts, 
compared to all other cell types (Figure 4B). 
 
The 30 Gene Stromal Classifier overlaps with the CMS4 subtype 
We next interrogated an independent stage II/III colon cancer dataset (2). Using a 
semi-supervised clustering approach, we identified a subset of tumors accounting for 
20% of the overall cohort that were positive for the 30 gene Stromal Classifier. Of 
these tumors, almost 90% are associated with the previously reported stem-like 
(CMS4) poor prognostic group (2) (Figure 5A). These findings show that the genes 
which are differentially expressed between the central and invasive front regions of a 
primary tumor can identify patients exhibiting a poor prognostic “stem cell-like” 
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mesenchymal biology. Additionally, in 2 further independent datasets GSE14333 (a 
mixed Stage II/III dataset (14)) and GSE33113 (an untreated stage II dataset (7)), 
the 30 gene Stromal Classifier consistently identified patients with a poorer 
prognosis, although these associations just failed to reach significance, most likely 
due to limited sample numbers (Figure 5B). 
 
To assess the extent that patient classification can be dictated by the tumor region 
sampled, we performed a reciprocal in silico analysis, in which the 48 samples 
representing IF and CT were classified using the genes previously published to 
classify the stem-like mesenchymal subtype (2). This analysis revealed 2 separate 
clusters, both highly enriched for samples based on the region-of-origin, with 75% of 
profiles originating from the IF being classified as stem cell-like (Figure 5C), 
compared to 33% for CT. 
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Discussion 
Region-specific transcriptional profiling allows precise dissection of the role of 
different tissue compartments in CRC disease biology, while also providing 
prognostic information on individual patients. Our results from 2 independent 
datasets GSE35620 (Figure 3A, 3B) and GSE6383 (Figure 3C) are in line with the 
recent stromal studies reported (11, 12) and further confirm that the key genes 
involved in classification of patient samples are derived from a stromal origin. These 
data collectively challenge the general assumption that tumors classified as 
mesenchymal, or in the CMS4 subgroup, have undergone widespread EMT, 
resulting in lower levels of epithelial associated traits in the tumor cell compartment, 
when actually these tumors have a higher component of stromal (particularly 
fibroblast), infiltration. Although immunohistochemistry-based analysis of CRC 
tumors has shown that neoplastic epithelial cells expressing stem-like properties 
have a poor prognosis (15-17), our findings emphasize that the CMS4 subgroup 
represents tumors with higher transcription levels of mesenchymal-associated 
genes, which can be attributed to their overall stromal-rich, and in particular 
fibroblast, architecture. 
 
While our data strongly suggest that the overall proportion of EMT in CMS4 tumors is 
not as extensive as first proposed, we did observe some evidence of localized loss 
of E-cadherin staining in a small proportion of budding cells (data not shown). 
Precise examination of these individual tumor buds may reveal the biology driving 
the invasive nature of individual cells compared to the overall tumor mass. Stromal-
epithelial interactions have a clear underlying role in the development of tissue and 
in the shaping of the microenvironment in both normal and malignant conditions. The 
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configuration of the tumor border region itself can also give insight into the prognosis 
of a patient, with a high degree of stromal infiltration into a tumor being a poor 
prognostic indicator (18, 19).  
 
While the finding that high levels of stromal infiltration are associated with poor 
prognosis is not new (11, 12, 18, 19), the present study precisely delineates the cell-
of-origin to the fibroblast compartment, with primary results validated in a 
comprehensive series of online datasets.  Data presented here, in addition to these 
referenced studies (12, 18-20) highlight that expression of a small number of genes 
in fibroblasts associated with the tumor, in combination with the overall fibroblast 
content, is sufficient to identify poor prognostic patients in stage II CRC. It is 
unsurprising therefore that the prognostic value of the CMS4 subtype, and indeed 
other current transcriptional-based prognostic classifiers, is highly dependent on 
stromal-derived gene signatures and that our 30 gene Stromal Classifier also 
identifies a group of patients with a worse prognosis. A combined classification 
system, utilizing clinical, morphological and molecular features, has been previously 
proposed and shown to provide a confident prediction of patient outcome (21). Multi-
region sequencing and mutational analysis has highlighted diversity in renal (22) and 
recently in CRC (23) patient samples, but our data shows that patient classification in 
CRC utilizing transcriptional profiling is associated as much with the region from 
where the sample is derived from, as with the underlying tumor biology. 
 
Implications of transcriptomic heterogeneity within CRC 
Data presented here shows for the first time that the recently published CRC CMS 
classification system (9) is dependent not just on the overall driving biology of a 
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tumor, but also on the region of sampling. We have shown that each individual 
primary tumor has the potential to be classified into a poor prognostic mesenchymal 
subtype if the tissue employed in the analysis is taken from the invasive front of the 
tumor, regardless of the inherent CMS subtype of the tumor overall. These findings 
may have important implications for the use of molecular classification approaches in 
selecting patients for therapeutic intervention in biomarker-driven stratified clinical 
trials. Given the lack of standardized procedures employed in tissue sampling for 
these transcriptional profiling approaches, our data provide cautionary evidence that 
a generic transcriptional profiling strategy, which does not consider the role of 
specific site of tissue origin within the tumor, could result in patient misclassification 
into inappropriate subgroups, leading to inaccurate prognostication and treatment 
that yields no benefit or may even potentially harm patients.  
 
A recent precision medicine-based clinical trial, the WINTHER study (24, 25) (an 
output of the Worldwide Innovative Networking in personalized cancer medicine 
(WIN) Consortium), aimed at selecting optimal innovative drug treatment strategies 
for patients with advanced metastatic tumors, has highlighted the utility of sampling 
matched normal and tumor biopsies from the same patient in order to identify novel 
therapeutic strategies based on differential gene expression in the neoplastic tissue 
compared to the normal sample. There are a number of clear similarities between 
the WINTHER study approach and the findings presented here, where the non-tumor 
component can inform prognosis, but while there seems to be clear rationale for this 
approach aimed at personalized drug selection, there may be only limited benefit 
derived by subtracting the results of adjacent normal or stromal tissue in order to 
correctly classify the overall tumor molecular subtype. As the defined CMS of CRC 
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are based on the presence and extent of infiltrating stroma, the subtraction of non-
tumor cell signaling would likely result in further misclassification, similar to what 
Isella et al. (11) reported following molecular subtyping of PDX implanted CRC tumor 
tissue.. Furthermore, our data and those of Isella et al (11) and Calon et al (12) also 
raise the important question as to which aspect of this stromal-tumor interface 
dictates aggressive tumor biology, and in turn, response to therapy.  
 
The primary tumor samples used in this study are predominantly from patients with 
non-metastatic disease (92% stage II/III – Supplementary Table 1) and as such 
represent samples with limited molecular heterogeneity compared to pretreated 
metastatic solid tumor samples  or samples from  advanced leukemia patients (e.g. 
blast crisis Chronic Myeloid Leukemia (CML)), both of  which can introduce further 
complicating issues when assessing prognosis and treatment response using 
molecular-based precision medicine approaches (26). While there is, as yet, no 
defined metastatic-specific CMS typing approach which captures transcriptional 
changes associated with liver and lung tissue infiltration, there will inevitably be 
variations in the stromal content of metastatic lesions in both the liver and lung 
similar to what we have presented here in the primary setting. The prognosis of 
tumors with high metastatic site-specific stromal infiltration may not equate to that of 
high levels of fibroblast infiltration in primary CRC tumors, and in a similar scenario 
to blast crisis CML, it is clear that putative treatment regimes for molecularly 
heterogeneous metastatic neoplastic lesions from solid tumors require very careful 
consideration in order to achieve therapeutic success (26). 
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In conclusion, the data we have presented here, alongside other recent publications 
(11, 12), question the contribution of tumor epithelial cells to CRC gene expression 
signatures and emphasize the need to value the role of stromal-derived signatures in 
modulating CRC biology. Furthermore, they also provoke a cautionary re-evaluation 
of the thesis of several recent publications (2-4) (including the CRCSC CMS paper 
(9)) that molecular classification, irrespective of tumor tissue site of origin, can be 
reliably employed to underpin treatment algorithms in CRC. We propose that a 
morpho-molecular strategy (27), integrating tissue morphology/origin, molecular 
evaluation (e.g. gene expression profiling, next generation sequencing, tissue 
microrarray analyses) and clinical phenotype in a common integromics framework 
(28), is necessary for precise, robust and clinically-relevant dissection of tumor 
biology that will inform the next generation of investigator-led biomarker-driven 
interventional trials in this common disease. 
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Figure legends 
 
Figure 1: Differential analysis and classifier generation. 
A. Venn diagram, produced using limma, of numbers of probesets which are 
differentially expressed between each region (IF = Invasive Front; CT = Central 
Tumor; LN = Lymph Node). The total number of differentially expressed genes 
increases as spatial distance from the central tumor increases. The number of 
probes which do not appear in any of the three Venn sets is displayed in the bottom 
right. This indicates that there are very small but robust differences in the 
transcriptome of the CT compared to the IF B. Volcano plot depicting highest ranked 
differentially expressed genes between the central and invasive front regions. Gene 
symbols corresponding to each individual probeset identified are depicted. C. 
Heatmap of central and invasive front samples clustered by expression values of the 
30 genes in the supervised invasive classifier. Overlay bar depicts the region from 
which the sample originated, with black representing the central tumor and grey 
representing invasive front samples, confirming the robustness of the 30 genes used 
in classifying samples based on region-of-origin. 
 
Figure 2: Ordination of samples by region-of-origin based on previously 
published stromal-specific gene signature 
Correspondence analysis depicting a strong separation and grouping of the CT, IF 
and LN samples according to their region-of-origin using the most variant probes  
from the Isella et al. 213 stromal-specific gene signature following cross annotation 
(top quartile). Left pane depicts the projection of individual samples with the right 
pane depicting the grouping with ellipse and star arguments. These findings highlight 
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the role of the non-tumoral transcriptome on the intratumoral heterogeneity of 
primary CRC tumor tissue analysis. 
 
Figure 3: Stromal derived gene transcripts underpin sample classification 
according to region-of-origin  
A. Heatmap based on expression values of the genes from our supervised stromal 
classifier which are highly expressed at the invasive front can stratify samples 
according to tissue type in GSE35620, which contains transcriptional profiles of 
microdissected primary CRC tumors purified into epithelial and stromal 
compartments. B. PCA plot from sample distribution based on clustering in A, again 
validating the utility of our classifier in identifying tissue type. C. Heatmap based on 
expression values of genes from the stromal classifier which are highly expressed at 
the invasive front, using transcriptional profiles from GSE6383, which contains 
mouse intestinal tissue separated into epithelial and mesenchymal compartments. 
These finding highlight the stromal-specific source of the gene transcripts identified 
in our classifier. 
 
Figure 4: Specific cell of origin of transcriptional classifier 
A. Heatmap expression values of stromal classifier in GSE39396 of Fluorescence 
Activated Cell Sorting (FACS) selected cells into specific endothelial [CD45(+), 
EPCAM(-), CD31(-), FAP(-)], epithelial [CD45(-) EPCAM(+), CD31(-), FAP(-)], 
leukocyte [CD45(-), EPCAM(-), CD31(+),FAP(-)] and fibroblast [CD45(-), EPCAM(-), 
CD31(-), FAP(+)] populations which suggests upregulation of these transcripts in the 
cancer-associated fibroblast compartments compared to the other compartments of 
the tumor microenvironment. B. These findings were confirmed by median 
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normalizing and plotting each gene using dot-plots according to specific cell type. 
Median value for overall gene expression in each cell type is indicated. Error bars 
indicate standard deviation. 
 
Figure 5: Prognostic value and patient stratification using transcriptional 
profiling is based on stromal derived genes. 
A. Identification of an invasive-like cluster, accounting for 20% of the patient cohort, 
using our supervised stromal classifier and expression data from a large well 
characterized stage II/III CRC dataset; GSE39582. This cluster strongly identifies the 
previously characterized stem-like C4 (CMS4) poor prognostic group with a 
sensitivity of 89% and specificity of 87%. B. Euclidean clustering and survival 
analysis using our stromal classifier in GSE14333 (top panels) and GSE33113 
(bottom panels). The stromal classifier isolates a subgroup of patients accounting for 
between 21-26% of each cohort, with a trend towards a worse prognosis compared 
to remaining patients (HR=1.942 in GSE14333 and HR=2.914 in AMC-AJCCII-90). 
C. Heatmap depicting Euclidean clustering of central and invasive front samples 
using previously reported stem-like patient classifier (2). This poor prognostic 
classifier defines two distinct groups, based on clustering distance, which are highly 
stratified based on region-of-sampling using the most variant probes (top quartile). 
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Table 1: 30 gene classifier of tumor region. 
Top 30 ranked genes across returned from our supervised analysis giving the lowest 
misclassification rate, which can identify the region-of-origin when using multiple 
samples from the primary tumor with a PPV and NPV of 91.7%. The top 20 genes (in 
red) are over-expressed in the invasive front samples compared to the central tumor, 
whereas the bottom 10 genes (in green) are over-expressed in the central tumor 
samples compared to the invasive front. This machine learning derived 30 gene 
classifier can identify tumor tissue based on region-of-sampling as shown in Figure 
1C. 
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Symbol Entrez Gene Name
ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9
ABI3BP ABI family, member 3 (NESH) binding protein
C7 complement component 7
CASQ2 calsequestrin 2 (cardiac muscle)
CILP cartilage intermediate layer protein
CILP2 cartilage intermediate layer protein 2
FABP4 fatty acid binding protein 4, adipocyte
HSPB6 heat shock protein, alpha-crystallin-related, B6
IGF1 insulin-like growth factor 1 (somatomedin C)
LONRF2 LON peptidase N-terminal domain and ring finger 2
MGP matrix Gla protein
MYOM1 myomesin 1
PTGIS prostaglandin I2 (prostacyclin) synthase
SFRP1 secreted frizzled-related protein 1
SFRP2 secreted frizzled-related protein 2
SLIT3 slit homolog 3
SYNPO2 synaptopodin 2
TGFB3 transforming growth factor, beta 3
WT1 Wilms tumor 1
ZBTB16 zinc finger and BTB domain containing 16
CXCL1 chemokine (C-X-C motif) ligand 1
CXCL5 chemokine (C-X-C motif) ligand 5
CXCL8 chemokine (C-X-C motif) ligand 8
HCAR3 hydroxycarboxylic acid receptor 3
IL1B interleukin 1, beta
MMP1 matrix metallopeptidase 1 
MMP3 matrix metallopeptidase 3
REG1A regenerating islet-derived 1 alpha
WNT5A wingless-type MMTV integration site family, member 5A
LCN1 lipocalin 1
Table 1 
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